A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer

Cancer

Volumn 117, Issue 1, 2011, Pages 103-109

  Lughezzani, Giovanni ^a,b   Sun, Maxine ^a   Shariat, Shahrokh F ^c   Budaüs, Lars ^a,d   Thuret, Rodolphe ^a,e   Jeldres, Claudio ^a,f   Liberman, Daniel ^a,f   Montorsi, Francesco ^b   Perrotte, Paul ^f   Karakiewicz, Pierre I ^a,f  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIV MONTPELLIER   (France)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

bladder cancer; elderly; Poisson regression; radical cystectomy; survival; tumor stage

Indexed keywords

ADULT; AGE; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HEART DISEASE; HUMAN; INFORMED CONSENT; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; PELVIS LYMPH NODE; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEX RATIO; TRANSITIONAL CELL CARCINOMA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; CYSTECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POPULATION SURVEILLANCE; RISK ASSESSMENT; SEER PROGRAM; URINARY BLADDER NEOPLASMS;

EID: 78650701254     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25345     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
2. Stenzl A, Cowan NC, De Santis M, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2009; 55: 815-825.
3. Sylvester R, Sternberg C., The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol. 2000; 11: 851-856.
4. Isbarn H, Jeldres C, Zini L, et al. A population based assessment of perioperative mortality after cystectomy for bladder cancer. J Urol. 2009; 182: 70-77.
5. Albertsen PC, Hanley JA, Gleason DF, et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998; 280: 975-980.
6. Hollingsworth JM, Miller DC, Daignault S, et al. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007; 109: 1763-1768.
7. National Cancer Institute. SEER Cancer Statistics Review, 1975-2004. Available at: http://seer.cancer.gov/csrAccessed on January 15, 2009.
8. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19: 666-675.
9. Konety BR, Joslyn SA., Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol. 2003; 170: 1765-1771.
10. Nielsen ME, Shariat SF, Karakiewicz PI, et al. Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol. 2007; 51: 699-706.; discussion 706-708.
11. Yamanaka K, Miyake H, Hara I, et al. Significance of radical cystectomy for bladder cancer in patients over 80 years old. Int Urol Nephrol. 2007; 39: 209-214. (Pubitemid 46722968)
12. Koppie TM, Serio AM, Vickers AJ, et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer. 2008; 112: 2384-2392.
13. Gore JL, Lai J, Setodji CM, et al. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer. 2009; 115: 988-996.
14. Clark PE, Stein JP, Groshen SG, et al. Radical cystectomy in the elderly: comparison of survival between younger and older patients. Cancer. 2005; 103: 546-552.
15. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006; 176 (6 pt 1): 2414-2422. discussion 2422.
16. Resorlu B, Beduk Y, Baltaci S, et al. The prognostic significance of advanced age in patients with bladder cancer treated with radical cystectomy. BJU Int. 2009; 103: 480-483.
17. Figueroa AJ, Stein JP, Dickinson M, et al. Radical cystectomy for elderly patients with bladder carcinoma: an updated experience with 404 patients. Cancer. 1998; 83: 141-147.
18. Clark PE, Stein JP, Groshen SG, et al. Radical cystectomy in the elderly: comparison of clinical outcomes between younger and older patients. Cancer. 2005; 104: 36-43.
19. Kircher T, Nelson J, Burdo H., The autopsy as a measure of accuracy of the death certificate. N Engl J Med. 1985; 313: 1263-1269.
20. Hall R., Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer. Proc Am Soc Clin Oncol. 2002; 21: 178(a). Abstract 710.
21. Grossman H, Natale R, Tangen C, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859-866.
22. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003; 361: 1927-1934.
23. Porter MP, Kerrigan MC, Donato BM, Ramsey SD., Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol. [publishedonline ahead of print May 16, 2009.]